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Abstract
Chikungunya fever is an acute febrile illness caused by the chikungunya virus (CHIKV), which is 
transmitted to humans by Aedes mosquitoes. Although chikungunya fever is rarely fatal, patients 
can experience debilitating symptoms that last from months to years. Here we comprehensively 
assess the global distribution of chikungunya and produce high-resolution maps, using an 
established modelling framework that combines a comprehensive occurrence database with 
bespoke environmental correlates, including up-to-date Aedes distribution maps. This enables 
estimation of the current total population-at-risk of CHIKV transmission and identification of 
areas where the virus may spread to in the future. We identified 94 countries with good evidence 
for current CHIKV presence and a set of countries in the New and Old World with potential for 
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future CHIKV establishment, demonstrated by high environmental suitability for transmission and 
in some cases previous sporadic reports. Aedes aegypti presence was identified as one of the major 
contributing factors to CHIKV transmission but significant geographical heterogeneity exists. We 
estimated 1.3 billion people are living in areas at-risk of CHIKV transmission. These maps 
provide a baseline for identifying areas where prevention and control efforts should be prioritised 
and can be used to guide estimation of the global burden of CHIKV.
Introduction
Recent emergence and re-emergence of chikungunya virus (CHIKV) in several regions 
globally underscores the importance of implementing and strengthening surveillance 
systems for rapid and accurate case identification [1]. CHIKV causes an acute febrile illness 
with severe arthralgia [2]. It is a mosquito-borne pathogen of the genus Alphavirus and 
transmitted to and between humans by Aedes mosquitoes with four circulating genotypes 
[3,4]. In the eastern part of Africa CHIKV is sustained in an enzootic, sylvatic cycle that 
involve arboreal mosquito vectors and non-human primates [5]. Clinical manifestations of 
the disease usually include fever, rash and arthralgia, which are similar to dengue symptoms, 
potentially leading to misdiagnosis and underreporting in the absence of specific laboratory 
diagnostic testing [6]. CHIKV and dengue also share the same primary vector Ae. aegypti 
and occasional co-infection has been reported [7]. Although it has been shown that also Ae. 
albopictus can transmit the virus between humans such outbreaks have been more localised 
[8]. Mortality from CHIKV infection is rare, infected persons can experience prolonged joint 
pain and arthritis over a period of months to years. There are also no antiviral agents or 
treatments for chikungunya fever (CHIK), but candidate vaccines are under development [9].
In 2013, the first autochthonous transmission of CHIKV in the western hemisphere was 
reported on Saint Martin Island in the Caribbean. The outbreak subsequently spread to 
several Caribbean islands and the wider Americas (including many countries in Central and 
northern South America), reaching over one million suspected and confirmed cases by 
December 2014 [10] due to the presence of a large naïve population and competent vectors. 
Despite an increasing global spatial distribution and clinical significance, detailed spatial 
information of the global geographical extent of CHIKV remains sparse. Previous work has 
mostly focused on assessment of CHIKV presence at a country level [1]. A comprehensive 
assessment of CHIKV transmission records globally is critical to identify knowledge gaps 
and regions where preventive and targeted control efforts should be prioritised. Additionally, 
this information can be used to guide estimation of the global clinical burden of CHIKV, 
which is currently unknown. Studies on the prediction of future trends and possibility of 
transmission in unaffected regions would also benefit from a thorough evaluation of the 
contemporary distribution and mapping of the extent of CHIKV on a fine spatial scale.
To assess the global distribution of CHIKV, we adopt established disease mapping 
approaches [11] previously used for dengue [12,13], Zika [14], and the leishmaniases [15]. 
We developed a comprehensive database of unique locations where CHIKV transmission has 
been reported and an evidence consensus score – a summary statistic of evidence for 
CHIKV presence or absence using a weighted scoring system [13]. We then couple these 
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data with a comprehensive set of environmental correlates and contemporary Aedes 
distribution maps in a species distribution model to generate high-resolution risk maps (5km 
× 5km), representing environmental suitability for CHIKV transmission and to derive 
population-at-risk estimates. These maps and estimates can be refined as new data on 
disease and vector range expansion become available.
Methods
Occurrence records
Data on CHIKV transmission events were obtained from peer-reviewed literature, health 
organisations, and supplementary evidence such as, data on vector presence. A 
comprehensive review of peer-reviewed literature was initially conducted on 4 April 2014 in 
PubMed using the search term ‘chikungunya’. The data were subsequently updated every 
month until 7 May 2015. A total of 2,120 articles were identified. Abstracts of all articles 
were read to identify those that possibly included geographical information of clinical cases, 
epidemiological records or outbreaks of CHIKV. Information was extracted on: (i) date of 
occurrence, (ii) type of event (autochthonous vs imported cases), (iii) number of cases, and 
(iv) the geographical location (latitude, longitude and administrative level) following a 
standard protocol [16]. If people were diagnosed after returning from travel but the location 
of infection could be identified unambiguously due to information on the travel history, the 
data were retained. Of the 2,120 articles, 339 were used, resulting in 463 unique occurrence 
points.
We also consulted health organisation webpages, including the World Health Organization 
(WHO), Pan American Health Organization (PAHO), Global Infectious Disease and 
Epidemiology Network (GIDEON) and the United States (US) Centers for Disease Control 
and Prevention (CDC). Data on recent and ongoing outbreaks in the Americas were obtained 
from weekly PAHO epidemiological reports. Since PAHO is a WHO affiliate organisation, 
PAHO and WHO data were combined to represent a single health organisation data source 
resulting in 65 unique occurrence points.
Finally, 600 occurrence points based on reports of CHIKV outbreaks were obtained from the 
online surveillance system, HealthMap (http://www.healthmap.org/en).
Each location was then classified as precise (e.g. a town) or an administrative unit and the 
latter were linked to the appropriate polygon information from the Global Administrative 
Unit Layers dataset (http://www.gadm.org). Each occurrence point was attributed to a 
specific location (latitude and longitude) based on the level of detail presented in the data 
source. We used Google Maps (https://www.google.co.uk/maps) to support the 
geopositioning. The database subsequently underwent temporal and spatial standardisation 
using a standard protocol described elsewhere [16]. We removed any duplicate records so 
that the resulting database contained only one occurrence record per spatial entity. Further, 
any records reported from the above mentioned data sources that fell outside land borders 
(e.g. due to wrong geopositioning of the original source) were removed. Occurrence records 
were then cross-checked manually and for each occurrence point, the probability of 
occurrence for both vectors was extracted (Figure 1c and d) and records deemed implausible 
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(probability of occurrence for both vectors individually fell below 70%) [17] were removed. 
The cut-off at 70% was chosen based on a qualitative interpretation of the Ae. aegypti and 
Ae. albopictus probability of occurrence maps, where > 90% of the geographical spaces with 
non-zero probabilities were recorded between vector presence 70% to 100%.
Evidence consensus
The evidence consensus is a summary statistic representing confidence in the presence or 
absence of CHIKV for a given political region. We calculated evidence consensus scores at a 
national level for all countries apart from Argentina, Brazil, China, France, India, Italy, 
Mexico, and the US, where sufficient detailed epidemiological information was available to 
distinguish within-country epidemiological, environmental, and economic variability. 
Smaller countries were not considered for subnational assessment.
Each evidence category was scored independently and category weights applied to reflect 
the level of detail each category provides: health organisation status (max. score 6), peer-
reviewed evidence (max. 9), case data (max. 9) and supplementary evidence (max. 6). For 
example, if all three health organisations considered (i.e. PAHO/WHO, GIDEON and CDC) 
agreed on presence/absence of CHIKV, the country was assigned a score of + 6/-6. If two 
health organisations agreed on presence/absence, the country was assigned a score of + 3/-3. 
For each country, we identified peer-reviewed evidence to confirm CHIKV presence based 
on seroprevalence studies, polymerase chain reaction (PCR) confirmation, case reports and 
local outbreaks. Each published study was scored independently based on date of disease 
occurrence and the average was taken and added to a score of accuracy, which was assigned 
based on diagnostic procedure. The case data category was scored based on the most recent 
outbreak year and pre-defined inter-epidemic period intervals to account for herd immunity 
[18,19]. In the absence of case data, healthcare expenditure (HE) was used as a proxy to 
indicate confidence in a country’s ability to detect and report CHIKV cases and to 
supplement this category [13]. In addition, countries for which HE data were unavailable 
were assigned low HE, and overseas territories were assigned the same HE as their parent 
nations.
For areas with conflicting reports from the input sources and recent geographical expansion 
(e.g. Mexico and Brazil), database records were crosschecked against expert knowledge and 
recent national reports. Supplementary evidence was extracted from peer-reviewed literature 
on mosquito presence, dengue presence, travel advisories (http://www.nathnac.org/travel), 
and the HealthMap database (http://www.healthmap.org) and scored based on number of 
evidence types. The HealthMap database contains data extracted from online news sources 
and alerts from official public health sources (e.g. ministries of public health) and was 
available from 2006 to 2014. We also used data on the global evidence consensus on dengue 
transmission from Brady et al. [13] to supplement data on the presence of other arboviruses 
for each country. See Table 1 for a summary and Brady et al. [13] for additional details on 
the scoring process.
The scores from all previously described evidence categories were summed, divided by the 
maximum potential score, 30 and multiplied by 100. The evidence consensus was then 
mapped based on seven equidistant categories: complete evidence for presence (›71.42 to 
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≤100) or absence (›-100 to ≤-71.42), good evidence for presence (›42.84 to ≤71.42) or 
absence (›-71.42 to ≤-42.84], moderate evidence for presence (›14.27 to ≤42.84) or absence 
(›-42.84 to ≤-14.27), and indeterminate evidence (>-14.27 to ≤14.27).
Environmental risk maps
A boosted regression tree (BRT) modelling approach was applied to derive probabilistic 
global environmental risk maps for CHIKV. BRT models combine the strengths of 
regression trees with boosting and are frequently used in species distribution modelling 
(SDM) [20] with the overall aim to identify areas that exhibit similar conditions to areas 
where the disease has been reported. These statistical models heavily depend on the input 
occurrence database. We included the following globally available environmental and 
socioeconomic covariates in our models: (i) probabilistic global niche maps for Ae. aegypti 
and Ae. albopictus [17]; (ii) land surface temperature (LST); (iii) a categorical 
differentiation in urban, peri-urban and rural environments, as well as their accessibility; and 
(iv) enhanced vegetation index (EVI).
Aedes aegypti and Aedes albopictus suitability—We constructed probabilistic 
global Aedes risk maps based on the most comprehensive globally representative occurrence 
dataset for both Ae. aegypti and Ae. albopictus species and a set of contemporary 
environmental covariates explaining their global distribution (Figure 1c and d) [17,21].
Land surface temperature (LST)—Temperature is one of the most important 
determinants of Aedes survival [22]. We used MODIS daytime LST after processing through 
a gap-filling algorithm to account for variation in temperature globally [23] (Figure 1g and 
h). Additionally, transmission of CHIKV is dependent on the persistent presence of the 
disease vectors, Ae. aegypti and Ae. albopictus mosquitoes. Both adult female longevity and 
length of first gonotrophic cycle are temperature dependent. We used the combined 
temperature suitability of population persistence for both species to identify areas where by 
proxy we expect the geographical limits of transmission of CHIKV to be located [13,15]. 
The binary outputs of this model were used as a mask to exclude the placement of 10,000 
pseudo-absences inside their physiologically plausible range.
Enhanced vegetation index (EVI)—Water availability is another important factor for 
CHIKV transmission, as it has been shown, for example, that mosquitoes may cluster around 
houses if containers with standing water due to precipitation are present [24]. EVI measures 
vegetation canopy greenness and can be used as a proxy for soil surface-level moisture that 
are associated with the presence of vector larval development sites [25]. We used range and 
mean values of MODIS EVI after processing through a gap-filling algorithm described in 
Weiss et al. [23] (Figure 1e and f).
Urbanisation—To account for differences in urban, peri-urban and rural environments we 
built a categorical variable by supplementing the projected 2010 Global Rural Urban 
Mapping Project (GRUMP) urban rural categories with land-cover classes using night-time 
light satellite imagery and population density based on the most up-to-date national censuses 
available at the smallest available administrative unit [26]. A gridded surface of 5 km × 5 km 
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cells was generated with each pixel representing urban, peri-urban, or rural areas (Figure 
1b).
Urban accessibility—Human movement defines the spatial scale of transmission of most 
communicable diseases. To account for areas that are highly accessible, we used a friction 
surface that shows pixel level travel time through the respective region of interest [27] 
(Figure 1a).
We then applied an ensemble BRT using 180 submodels to derive probabilistic estimates and 
underlying uncertainty at a 5 km × 5 km resolution. We also estimated populations-at-risk of 
CHIKV transmission. For each occurrence record we identified the maximum risk 
probability of transmission within a buffer of 10 km around the occurrence record to derive a 
threshold value of probability of occurrence that should be included in the population-at-risk 
estimate. We then converted the continuous surface of transmission risk into a binary at-risk/
not-at-risk classification. Finally, we extracted the population living in areas of potential 
transmission using a global population surface.
Results
The data abstraction yielded 528 occurrence points from peer-reviewed evidence and health 
organisations. The distribution of occurrence points by region is shown in Figure 2. 
Individually, WHO (+ PAHO), CDC and GIDEON implicated 60, 96, and 70 countries with 
reported CHIKV transmission, respectively. However, based on evidence from all available 
sources, we identified 94 countries with good or better evidence consensus on CHIKV 
presence from which 47% were in Asia and Africa and 44% in the Americas. Of the 94 
countries, at total of 24, 41, 20, two and seven were located in Africa, the Americas, Asia, 
Europe and Oceania, respectively.
High probability of Ae. aegypti occurrence was the strongest predictor for environmental 
suitability with a mean contribution of 46% (Table 2). Based on our environmental 
suitability predictions, we estimate that 1.3 billion people are living in areas of potential 
CHIKV transmission.
Global consensus on CHIKV presence or absence based on the evidence consensus scoring 
system and predictions of environmental suitability for CHIKV are further presented in for 
Africa and Europe, the Americas, and Asia and Oceania, respectively. The evidence ranges 
from complete presence to complete absence.
Africa and Europe
Most of the African countries with reliable evidence on presence and absence were located 
in Central and North Africa, respectively. The strong evidence for CHIKV presence in 
Central Africa was aided by in-country seroprevalence studies such as in Cameroon and 
Gabon and confirmed imported cases to non-endemic regions [28,29]. There was insufficient 
data to determine presence or absence for some countries in Africa such as Ghana, Ethiopia, 
and Mozambique, due to a general lack of data and poor surveillance. South Africa, for 
example, had a reported outbreak in 1977 [30], but there have been no new reports of 
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outbreaks or seroprevalence studies. Most countries in Central and parts of West Africa with 
strong evidence on CHIKV presence also demonstrated high environmental suitability for 
CHIKV (Figure 3b). We estimated that over 240 million people live in areas at risk for 
CHIKV transmission in Africa.
Autochthonous transmission of CHIKV in Europe has been reported in Ravenna, northern 
Italy in 2007 and in the south-eastern French city of Fréjus in 2010 and Montpellier, 
southern France in 2014 (Figure 3a). Prior to these cases, CHIKV in Europe was limited to 
travel-related cases. Genomic micro-evolution of CHIKV in Reunion facilitated transmission 
by Ae. albopictus [31] in strains belonging to the so called Indian Ocean lineage (IOL) 
which increased the likelihood of CHIKV outbreaks in Europe. We predicted moderate 
environmental suitability for parts of France, Spain, Germany and Italy (Figure 3b), which is 
in agreement with previous projections of increased risk of CHIKV for France, northern 
Italy and the Pannonian Basin [32].
Americas
Systematic reporting of confirmed cases to PAHO provided well-documented evidence for 
CHIKV occurrence in the Americas. As of 13 March 2015, 45 countries had reported local 
transmission of CHIKV, while the evidence consensus identified 90% of countries and island 
states with good or better consensus (Figure 4a). Laboratory confirmation of autochthonous 
cases made a major contribution in defining the South and Central America’s higher 
consensus cluster on presence. The evidence strength varied across states for Brazil and 
Mexico. Brazil had strong evidence on presence in south-central states; indeterminate 
evidence for several southern states and Amazonas state in the north; and moderate evidence 
in central and northern states. In contrast, the environmental suitability map predicted that 
coastal Brazil and areas in the Amazon were highly suitable for CHIKV transmission. Peru 
and states in Brazil where evidence currently suggest absence, demonstrated a moderate to 
high suitability for CHIKV (Figure 4b).
Our models identified Ae. aegypti as the strongest predictor of CHIKV suitability, which is 
the primary vector implicated in the outbreak in most of the Caribbean and the Americas 
[33,34]. Based on the environmental suitability predictions, we estimated that over 260 
million people live in areas at risk for CHIKV transmission in the Americas.
Asia and Oceania
CHIKV presence is well documented for most countries and islands in south and south-east 
Asia. Persistent vector populations and naïve populations contributed to notable pre-2000 
CHIKV outbreaks in India, Myanmar/Burma, Philippines, Sri Lanka, Thailand and Vietnam 
[35,36]. In the last decade, outbreaks have been reported in India, Indian Ocean islands, 
Indonesia, Sri Lanka, and Thailand, following a 41-year period of quiescence [37,38]. Good 
to better consensus on CHIKV presence was reported for 80% of Asian countries and 
clusters of complete consensus were observed ranging from Myanmar/Burma to Vietnam for 
south Asia and Indonesia to Papua New Guinea for south-east Asian islands (Figure 5a). 
Complete consensus on CHIKV presence was noted for Guangdong province, China, where 
an outbreak was reported in 2010 [39]. With the exception of Chhattisgarh in Central India 
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and smaller states in the north-east and north-west, most Indian states had good consensus 
on CHIKV presence. There was insufficient data on presence or absence of CHIKV in 
Nepal. Despite reports of large outbreaks in neighbouring India and indication of possible 
local transmission, there are no published national seroprevalence surveys for Nepal and 
CHIKV cases are possibly misdiagnosed as typhoid or other bacterial or viral fevers [40].
The environmental suitability map strongly complemented the evidence consensus with high 
risk of CHIKV transmission predicted for most south-east Asia islands and parts of south-
east Asia, and moderate risk predicted for India (Figure 5b). Predictions of suitability for 
CHIKV transmission in China were patchy, with high risk predicted for regions where local 
CHIKV transmission has been observed. High prevalence has been noted for other arboviral 
diseases in southeast coastal regions, and northern and inland regions [41,42], signalling 
suitability and risk for CHIKV transmission. We estimated that over 270 million people live 
in areas at risk for CHIKV in Asia.
Discussion
We present the global distribution and predict environmental suitability for CHIKV 
transmission. In this analysis we combined extensive evidence available at multiple 
geographical scales and integrated them into a well-established disease mapping approach. 
We identified areas particularly in Africa where CHIKV status is uncertain (e.g. Ethiopia, 
Mozambique) although there is high environmental suitability, presence of disease vectors 
and reported outbreaks in neighbouring countries such as Tanzania. We also predicted high 
environmental suitability for some regions but observed moderate evidence for absence of 
local transmission, such as in the Amazon basin. The former could be attributable to 
inadequate surveillance or misdiagnosis, while the latter could be explained by the recent 
emergence of CHIKV and the endemicity of dengue in these regions. Our comprehensive 
assessment of these evidence gaps enables the identification of areas where surveillance, 
seroprevalence studies, and vector control measures are increasingly important [43].
Despite the growing economic and public health impact of CHIKV outbreaks, there have not 
been any thorough assessments of knowledge gaps or high-resolution distribution maps of 
the disease. This is the first comprehensive assessment of the current spatial extent and 
environmental suitability of CHIKV transmission globally. We considered extensive 
available evidence from 1952 when CHIKV was first identified in Tanzania. We observed 
the following: (i) CHIKV evidence is dynamic, re-emerging and due to its high attack rate 
likely to cause outbreaks with significant timelags; (ii) misclassification and delay in 
reporting may influence the perception of current vs. former presence; (iii) while there is 
strong evidence for some areas (e.g. Asia), data on CHIKV occurrence in many parts of 
Africa remain sparse.
Similar to dengue [44], CHIK appears to be an under-recognised problem in Africa. Our 
environmental suitability maps indicate moderate to strong risk for CHIKV transmission in 
most of West, Central and East African countries. However, there is insufficient data to 
determine presence or absence for several countries in West Africa and parts of East Africa. 
Seroprevalence surveys are needed for countries with indeterminate status.
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Additionally, co-occurrence and comorbidity of CHIKV and other arboviruses have been 
reported, which stresses the importance for better diagnostic tests. Furthermore, since 
dengue and CHIKV share the same primary vectors, similar estimates for population-at-risk 
would be expected. Population at risk of dengue virus transmission has been estimated at 
3.97 billion people [13], which is far more than the 1.3 billion predicted for CHIKV. 
However, the estimates for dengue were derived on a national level, while our estimates are 
at a 5 km × 5 km spatial scale.
Improvements, such as the identification of the primary vector for each occurrence record 
can be made as new data become available. Particularly in Africa and Micronesia it is 
hypothesised that other mosquito vectors (Ae. afticanus, Ae. luteocephalus, Ae. furcifer-
taylori and Ae. hensilli) are responsible for transmitting CHIKV between humans [45]. Data 
on their geographical distribution however remains sparse and could not be integrated in the 
current analysis. Furthermore, since the maps are derived using long-term average covariate 
layers, they identify areas that are at risk of transmission at any time during the year but do 
not consider explicitly how seasonality or human mobility affects transmission; these factors 
influence the short and long-term dynamics of CHIKV transmission. In addition, there are a 
number of other factors that may influence the probability of infection that relate to social 
aspects, such as, housing quality, poverty, susceptibility of the population, and the use of air-
conditioning. Such factors were not included in our study since no reliable data are available 
on a global scale.
Furthermore, there are some challenges in developing a global model to predict 
environmental suitability for CHIKV transmission. For instance, although there have been 
reports of major outbreaks of CHIKV in India, the environmental suitability models 
predicted moderate environmental suitability for CHIKV in these regions. The spatial 
variability observed for India is similar to the Ae. albopictus distribution map [17]. This 
suggests that our modelling approach strongly mirrors Ae. albopictus distribution in India, 
which has been implicated in recent outbreaks, but fails to capture the distribution of other 
covariates. Similarly, in Europe where there have been documented outbreaks of CHIKV in 
France, and Italy, risk appears to be low in our prediction. Modelling the likely distribution 
of CHIKV based on Ae. albopictus which is well distributed in southern Europe could help 
refine our approach. However, as transmission of CHIKV is relatively low in Europe, our 
results indicate the likely lower relative global contribution of Ae. albopictus compared with 
Ae. aegypti. Additionally, our maps indicate high transmission risk in small island states that 
have experienced large outbreaks in the last decade. However, herd immunity was not 
incorporated into the environmental risk models, implying that small countries or islands 
with (> 50% attack rates) might have a lower risk of CHIKV outbreaks despite 
environmental suitability. These observations highlight the need for region or country-
specific modelling, which would be most beneficial for local public health policy decisions. 
These maps can however be used as baseline layers for future projections of CHIKV and 
compared with global maps of dengue [12].
Despite these limitations, the usefulness of these maps cannot be understated, especially 
given the CHIKV’s currently expanding range in the Americas and elsewhere. By 
synchronising the evidence consensus, environmental suitability prediction maps and 
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population at-risk estimates, areas most in need of CHIKV surveillance resources were 
identified. It is equally important that these maps are updated as soon as new information 
becomes available, such as recent reports of local CHIKV transmission in states of Brazil, 
and Peru and this will be achieved by incorporating the results of this study into the Atlas of 
Baseline Risk Assessment for Infectious Diseases (ABRAID, at www.abraid.ox.ac.uk).
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Figure 1. Environmental covariates used in this study to predict the global environmental 
suitability of chikungunya virus transmission
EVI: enhanced vegetation index; LST: land surface temperature.
A. Urban accessibility, with brown representing high relative accessibility to urban areas and 
yellow representing rural isolated areas; B. Urban, peri-urban and rural areas; C. Aedes 
aegypti suitability,with red representing high environmental suitability for the vector and 
blue representing low suitability; D. Ae. albopictus suitability, with red representing high 
environmental suitability for the vector and blue representing low suitability; E. EVI mean 
values, whereby dark green represents areas with year round vegetation growth and light 
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green represents areas with low moisture levels; F. EVI range; G. LST mean values, whereby 
orange represents high temperatures and yellow lower relative temperatures; H. LST range, 
with orange representing high variation throughout an average year and yellow representing 
little annual variation.
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Figure 2. Distribution per continent of chikungunya virus transmission occurrence points from 
peer-reviewed evidence and health organisations, 1952–May 2015
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Figure 3. Evidence consensus (a) and predicted environmental suitability (b) for chikungunya 
virus in Africa and Europe, as of May 2015
The colour legend for the evidence consensus ranges from red to blue, representing complete 
consensus on presence to complete consensus on absence. Indeterminate consensus is in 
yellow. Evidence consensus is presented at Admim1 level for Italy and France, and Admino 
level for all other countries. The predicted environmental suitability map is presented in 
similar colours with 1 and 0 representing most and least suitability for chikungunya virus, 
respectively.
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Figure 4. Evidence consensus (a) and predicted environmental suitability (b) for chikungunya 
virus in the Americas, as of May 2015
The colour legend for the evidence consensus ranges from red to blue representing complete 
consensus on presence to complete consensus on absence. Indeterminate consensus is in 
yellow. Evidence consensus is presented at Admin1 level for United States, Mexico, 
Argentina and Brazil, and Admin0 level for all other countries. The predicted environmental 
suitability map is presented in similar colours with 1 and 0 representing most and least 
suitability for chikungunya virus, respectively.
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Figure 5. Evidence consensus (a) and predicted environmental suitability (b) for chikungunya 
virus in Asia and Oceania, as of May 2015
The colour legend for the evidence consensus ranges from red to blue representing complete 
consensus on presence to complete consensus on absence. Indeterminate consensus is in 
yellow. Evidence consensus is presented at Admin1 level for India and China, and country 
level for all other countries. The predicted environmental suitability map is presented in 
similar colours with 1 and 0 representing most and least suitability for chikungunya virus, 
respectively.
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Table 1
Summary of evidence used for chikungunya virus transmission consensus scoring
Evidence category Score
Health organisation status
Number of health organisationsa reporting epidemics or local transmission of chikungunya virus
3 +6/-6
2 +3/-3
Peer reviewed evidence
Date of chikungunya virus transmission occurrence
2005–2015 3
1997–2004 2
Pre-1997 1
Diagnostic procedure
Polymerase chain reaction (PCR) 3
IgM/IgG-based enzyme-linked immunosorbent assay (ELISA) and haemaglutination inhibition 2
No specified test 1
Combination scoreb
3 typesb 3
2 typesb 2
1 typesb 1
Case data or health expenditure
Case data: most recent outbreak
0–7 years 9
7–14 years 6
14–21 years 3
28–35 years -3
≥35 years -6
If no case data: health expenditure in 2014
HE <100 USD + sporadic cases 6
HE <100 USD + sporadic cases 3
100 USD ≤HE ‹500 USD -3
HE ≥500 USD -9
Supplementary evidencec
Number of evidence typesc
4 typesc 6
3 typesc 4
2 typesc 2
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a
The three health organisations considered included (i) the United States Centers for Disease Control and Prevention (CDC), (ii) the Global 
Infectious Disease and Epidemiology Network (GIDEON) and (iii) the World Health Organization (WHO) and Pan American Health Organization 
(PAHO) taken together.
b
The types of evidences include (i) reports from health organisations, (ii) the date of chikungunya virus transmission occurrence, and (iii) the 
diagnostic procedure.
c
The types of evidences include (i) mosquito presence, (ii) dengue presence, (iii) travel advisories, and (iv) HealthMap.
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Table 2
Relative contribution of each covariate in explaining the global environmental suitability 
of chikungunya virus and 95% confidence interval, 1952–May 2015
Variable Mean (95% confidence interval)
Aedes aegypti 46.16 (43.45–48.74)
EVI mean and range 33.37 (29.71–36.94)
Urban accessibility 7.42 (6.52–8.50)
Ae. albopictus 6.70 (5.78–7.60)
LST mean and range 5.98 (4.83–6.90)
Urbanisation 0.30 (0.15–0.70)
EVI: enhanced vegetation index; LST: land surface temperature.
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